#USA #Atlanta #Nordic Pharma #LACRIFILL #SECO 2025

Nordic Pharma to Present at SECO 2025

Nordic Pharma, Inc., a key player in the pharmaceutical sector and subsidiary of Nordic Group B.V., is all set to display its cutting-edge Lacrimal Gel at the SECO 2025 conference. This significant global event will take place from February 26 to March 2 in Atlanta, Georgia, and is known for its impact on optometric education.

Introduction to the Poster Presentation

The company is particularly excited about the poster presentation titled "Novel Canalicular Gel for Lacrimal Occlusion Case Series," which will be presented by Dr. Mile Brujic, OD, FAAO from Premier Vision Group. This session focuses on the innovative Lacrimal Gel designed for treating conditions associated with dry eye disease, a common ailment among many people today.

The LACRIFILL Canalicular Gel

LACRIFILL Canalicular Gel is a novel formulation consisting of hyaluronic acid (HA), available in a convenient, pre-loaded syringe for single use. This product is administered through the punctum, delivering the gel into the canaliculus with a tiny cannula attached at the end of the syringe. This method is straightforward and minimizes discomfort, ensuring better patient compliance and effective treatment.

Clinical Success Stories

Dr. Brujic will discuss a case series involving three patients who presented with refractory dry eye disease. These individuals had previously utilized dissolvable plugs for six months without satisfactory results. After being treated with LACRIFILL Canalicular Gel, these patients exhibited significant improvements in both clinical symptoms and overall comfort.

Dr. Brujic stated, "LACRIFILL Canalicular Gel has proven to be something special in my practice. I have observed considerable corneal improvement and increased comfort in patients. Additionally, I've managed to perform more occlusions in my practice thanks to this innovative gel."

Importance of the SECO Conference

The SECO International conference is recognized as one of the largest optometric educational meetings worldwide, offering a platform for vision care professionals to explore the latest in research, technology, and treatments. Attendees gain valuable insights through cutting-edge exhibits and networking opportunities, fostering further advancements in patient care.

Nordic Pharma's Commitment

Phil Gioia, President of Nordic's U.S. team, expressed his enthusiasm for the results being obtained with LACRIFILL Canalicular Gel, stating, "The success of Optometrists using LACRIFILL Canalicular Gel as a treatment for dry eye, along with such favorable outcomes, excites us greatly. We continue our dedication to supporting Eye Care Professionals in their mission to manage dry eye conditions effectively.”

Event Details

Poster Presentation Information:

• - Title: Novel Canalicular Gel for Lacrimal Occlusion Case Series
• - Presenting Author: Mile Brujic, OD, FAAO
• - Date and Time: February 28, 2025, from 9:45 AM to 11:45 AM
• - Location: Georgia World Congress Center, Hall A-1 and A-2, Building A - Level 1, Optometry's Marketplace™

Furthermore, the details of the presented posters will be made available online following the event at SECO University. For additional insights on LACRIFILL Canalicular Gel or to place orders, visit lacrifill.com.

About Nordic Group B.V.

Nordic Group B.V. is a medium-sized, privately owned international pharmaceutical company dedicated to the development and commercialization of specialized products. The firm has made strategic acquisitions and targeted developments in areas such as Eye Care, Rheumatology, and Women's Health, establishing a robust presence in the European market and expanding its reach globally.

About Nordic Pharma, Inc.

Nordic Pharma, Inc. partners with established global biopharmaceutical companies to leverage its expertise in bringing advanced biotechnology medicines and sterile manufacturing practices to market. This capability positions Nordic Pharma at the forefront of innovative treatment solutions.

Looking Forward

With these advancements and ongoing commitment to research and development, Nordic Pharma is poised to make significant impacts in the field of dry eye management and beyond, advocating for improved patient outcomes and greater accessibility to effective treatment options.

• ---

For further inquiries, please contact:
Nordic Pharma, Inc.
Kate Popova
Project Contracts Manager
Phone: 610-285-1699
Email: [email protected]
Gail Feerrar
Director Sales and Marketing
Phone: 610-285-7152
Email: [email protected]